EUVIMEDEUVIMED entdecken
Crossref

Demographic Trends, Co-Alterations, and Imatinib Resistance across Genomic Variants in Gastrointestinal Stromal Tumors: An AACR Project GENIE Analysis

Hunter Stecko, Sidharth Iyer, Diamantis Tsilimigras, Timothy M Pawlik

Oncology · 2024

DOI: 10.1159/000541454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Hunter Stecko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Drug Resistance, Neoplasm, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract, the treatment of which represents a significant breakthrough in targeted cancer therapy. Given its overall rare nature, genomic differences and clinical implications between demographic groups have not been previously investigated.

Methods

Anonymized demographic, clinical, and genomic data from 1,559 GIST patients in the American Association for Cancer Research Project GENIE database were analyzed using cBioPortal and custom Python scripts. Data on patient demographics, genomic alterations, and co-occurrence genetic alerations were collected and classified according to clinical implications using the OncoKB database. χ2 tests for differences in genomic alterations were used across various demographic factors and mutual exclusivity analysis was employed to identify co-mutation patterns.

Results

Male patients demonstrated higher incidence of PDGFRA mutation (14.56% vs. 8.05%; p < 0.001), while female patients had higher likelihood of NF1 mutations (7.46% vs. 3.23%; p = 0.001). Asian patients had higher alteration rates at KIT (85.59%; p = 0.002). Co-occurrence analysis revealed KIT alterations frequently co-occurred with CDKN2A (q < 0.001), MTAP (q = 0.045), and PTEN (q = 0.056), while there was mutual exclusivity with PDGFRA (q < 0.001), NF1 (q < 0.001), and BRAF (q = 0.015). CDKN2A alterations co-occurred with MTAP (q < 0.001) and PIK3CA (q = 0.015), while being mutually exclusive with TP53 (q = 0.002) and NF1 (q = 0.007). Trends were similar among patients who had received no prior medical treatment. Imatinib-resistant mutations were more common among male patients (25.6% vs. 18.9%; p = 0.0056) and individuals under 55 (27.3% vs. 20.9%; p = 0.0228). Among patients with imatinib-resistant mutations, 77.78% had sunitinib resistance, while 70.25% maintained sensitivity to ripretinib.

Conclusion

Sex and race/ethnic differences in genomic alterations, as well as co-mutations, were prevalent among patients with GIST. Variations in mutational profiles highlight the importance of distinct genetic drivers that may be targeted to treat different patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsImatinib MesylateDrug Resistance, NeoplasmGastrointestinal NeoplasmsHumansMaleFemaleMiddle AgedMutationAgedAdultReceptor, Platelet-Derived Growth Factor alphaAntineoplastic AgentsAged, 80 and overProto-Oncogene Proteins c-kitSex Factors

Stichwörter der Autor:innen

Co-alterationGastrointestinal stromal tumorsGenomic variationProject GENIE

Substanzen

Imatinib MesylateReceptor, Platelet-Derived Growth Factor alphaAntineoplastic AgentsProto-Oncogene Proteins c-kitKIT protein, human

Autor:innen und Institutionen

  • Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
  • The Ohio State University College of Medicine, Columbus, Ohio, USA.

Zitieren

APA

Stecko, H., Iyer, S., Tsilimigras, D., & Pawlik, T. M. (2024). Demographic Trends, Co-Alterations, and Imatinib Resistance across Genomic Variants in Gastrointestinal Stromal Tumors: An AACR Project GENIE Analysis. Oncology. https://doi.org/10.1159/000541454

Vancouver

Stecko H, Iyer S, Tsilimigras D, Pawlik TM. Demographic Trends, Co-Alterations, and Imatinib Resistance across Genomic Variants in Gastrointestinal Stromal Tumors: An AACR Project GENIE Analysis. Oncology. 2024. doi:10.1159/000541454

BibTeX
@article{Stecko2024,
  author = {Stecko, Hunter and Iyer, Sidharth and Tsilimigras, Diamantis and Pawlik, Timothy M},
  title = {Demographic Trends, Co-Alterations, and Imatinib Resistance across Genomic Variants in Gastrointestinal Stromal Tumors: An AACR Project GENIE Analysis},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000541454}
}
Kostenlos starten →